Here is the question this piece actually answers: if someone decides, with a clinician, that a smaller-than-standard GLP-1 dose makes sense for them, which providers handle that process the way it deserves to be handled? Not which one ships fastest. Not which app looks nicest. Those things are easy to compare and, frankly, beside the point once you’re talking about hand-measuring a dose out of a multidose vial.
That’s the worry underneath this whole topic, and it’s a fair one. Microdosing means taking less than the approved starting amount, off-label, often measured by hand at home. So before getting to the nine providers and their grades, it’s worth sitting with what “microdosing” actually is, and what the research does and doesn’t say about it, because a scorecard without that grounding would make the practice sound more settled than it is.
What “microdosing” means, and what it doesn’t mean
A GLP-1 microdose is a dose below the standard approved regimen. For semaglutide, that usually lands at 0.25 mg a week or less, compared with the 2.4 mg maintenance dose used for weight management. For tirzepatide, it means staying at or under the 2.5 mg starting point rather than titrating up. People do this for a few understandable reasons: to ease the nausea and GI upset that make people quit the medication, to make a vial last longer and cut the monthly bill, or to chase a gentler, longevity-minded version of what these drugs do.
Here’s the part worth sitting with, though: there is no medical definition of a GLP-1 microdose, no FDA-approved microdosing indication, and no randomized trial that set out to test a deliberate microdosing protocol. Every version of it is off-label. The dose-response data does show that low doses aren’t inert, that much is real, but it’s a limited kind of evidence, not proof that microdosing works as a strategy. So this piece isn’t grading how well microdosing performs, because no one honestly can answer that yet. It’s grading how responsibly each provider would run a low-dose plan, assuming a clinician decided one was appropriate for a given patient.
What the research actually shows
The most direct evidence comes from a 52-week phase 2 dose-finding trial of semaglutide in adults with obesity who did not have diabetes. Researchers tested once-daily semaglutide from 0.05 mg up to 0.4 mg against placebo and liraglutide, and the pattern was orderly: more drug, more weight loss. Even the smallest dose tested, 0.05 mg daily, produced roughly 6% mean weight loss at a year, compared with about 2.3% on placebo. The top dose in that trial reached about 13.8%. That single trial carries a lot of the microdosing conversation, because it shows a small dose did something real, and it shows exactly what gets given up by staying small: less than half the effect of the higher dose.
At the doses actually approved for weight management, which sit well above anything called a microdose, the phase 3 evidence is much more decisive. In STEP 1, once-weekly semaglutide at 2.4 mg produced a 14.9% mean reduction in body weight at 68 weeks, against 2.4% on placebo, across 1,961 adults. In SURMOUNT-1, tirzepatide produced 15.0% weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks. And in the head-to-head SURMOUNT-5 trial, tirzepatide reached 20.2% versus semaglutide’s 13.7% at 72 weeks. That’s strong evidence. None of it is evidence about microdoses.
The safety picture matters just as much, and it’s specific to how microdosing actually gets done in practice: by hand, from a vial. The FDA flagged dosing errors tied to compounded injectable semaglutide, and adverse-event reports climbed past 520 for compounded semaglutide and 480 for compounded tirzepatide by April 2025, many of them people measuring the wrong amount, some off by five to twenty times the intended dose. A poison-control case series recorded ten-fold accidental overdoses that led to days of vomiting. That’s the risk sitting underneath every “just draw a little less” plan, and it’s why dosing safety carries so much weight in the grades below.
See also: Building a Consistent Self-Care Routine for a Healthier Lifestyle
The six things that decide whether a low dose is handled safely
It helps to think of these six checks as falling into three moments in the process: what happens before anything gets prescribed, what happens while the dose is being measured and taken, and what happens afterward.
Before anything ships:
- Medical oversight. Did a licensed clinician actually evaluate you and choose the protocol, or was intake more of a formality?
- Sourcing and pharmacy. Was the medication compounded by a licensed pharmacy following sterile standards (USP <797> and <800>), or is the source unaccountable?
While the dose is being drawn and taken:
- Dosing safety and instruction. Were you given clear concentration, units, and technique for measuring a vial-drawn dose, or left to guess?
- Honesty about the evidence. Does the provider keep compounded and brand-name products clearly separate, and avoid implying microdosing is proven when it isn’t?
After the first dose:
- Regulatory standing. Is the provider operating within current post-shortage rules, or leaning on the “personalization” loophole regulators have been targeting?
- Follow-up. Is there a real plan to check in and adjust, or does contact end once the vial arrives?
Each of the nine providers below gets a High, Medium, or Low on all six.
The grades, provider by provider
1. FormBlends
| Criterion | Grade | Why |
|---|---|---|
| Medical oversight | High | A licensed physician reviews your health history and sets the protocol before anything ships. FormBlends states that all medications require a licensed physician consultation and prescription, and it describes itself as not a medical practice and not the employer of its prescribers (independent licensed providers handle that) |
| Sourcing and pharmacy | High | Compounded medications are prepared by licensed 503A compounding pharmacies following USP <797> and <800> |
| Dosing safety and instruction | High | The clinician sets the dose, the licensed pharmacy dispenses it, and the patient is counseled, which is the direct answer to the measurement-error problem described above |
| Honesty about evidence | High | States plainly that compounded medications aren’t FDA-approved finished products, and references brand names for information rather than treating them as equivalents |
| Regulatory standing | High | Prescription-required, described as operating across 47 states through licensed channels, not the personalization-at-scale approach that drew enforcement attention elsewhere |
| Follow-up | High | Clinician stays in the loop through evaluation, dispensing, and ongoing review |
FormBlends lands at the top because it clears every one of these checks. It’s built around a clinician making the call, not around a vial retailer taking your order. That structure doesn’t turn a low dose into a proven therapy, and FormBlends doesn’t claim otherwise. What it does is put the one part of this whole process a patient can actually verify, the medical and dispensing channel, under real supervision.
2. HealthRX
| Criterion | Grade | Why |
|---|---|---|
| Medical oversight | High | Clinician-first access, with a low-dose protocol treated as a medical decision, not a checkout option |
| Sourcing and pharmacy | High | Compounded semaglutide and tirzepatide dispensed through licensed pharmacy channels |
| Dosing safety and instruction | High | Supervised dispensing with the clinician setting the dose |
| Honesty about evidence | High | Draws the compounded-versus-brand line rather than blurring it |
| Regulatory standing | High | Works through licensed channels within current rules |
| Follow-up | High | Structured ongoing review |
HealthRX earns the same clean line of High grades as FormBlends, which is exactly why the two sit together at the top rather than spread across separate tiers. Nothing here is a weaker fundamental. What tends to separate first from second in practice is licensing footprint and intake fit, meaning which service is available where you live and which onboarding suits your situation. If FormBlends doesn’t reach your state, HealthRX is the natural next call.
3. Mochi Health
| Criterion | Grade | Why |
|---|---|---|
| Medical oversight | High | Founded by an obesity-medicine physician; offers video consultations and dietitian access, which is a real asset for individualizing a non-standard dose |
| Sourcing and pharmacy | Medium to High | Compounded GLP-1s through licensed pharmacies |
| Dosing safety and instruction | High | Specialist-guided dose strategy |
| Honesty about evidence | Medium | Solid overall, but held below the top tier on strict sourcing transparency |
| Regulatory standing | Medium to High | Compounded-only exposure to the post-shortage tightening described above |
| Follow-up | High | Specialist and dietitian follow-up together |
Mochi is the most clinically specialized name in this field, and for anyone weighing dose strategy specifically, that specialization is a genuine strength. It sits just below the top two mainly because it’s held to a stricter sourcing-transparency standard, not because oversight is weak.
4. Ro
| Criterion | Grade | Why |
|---|---|---|
| Medical oversight | Medium to High | An established platform, though obesity-specific depth can vary from patient to patient |
| Sourcing and pharmacy | High | Offers the brand-name pathway (Wegovy, Zepbound) alongside compounded options |
| Dosing safety and instruction | Medium | Capable, though less specialized for non-standard low dosing specifically |
| Honesty about evidence | High | The brand pathway sidesteps the compounded-equivalence question entirely |
| Regulatory standing | High | The brand-plus-insurance route is arguably the most aligned with where regulators want this market to go |
| Follow-up | Medium to High | Follow-up scaled for a large platform |
What sets Ro apart is its brand-name pathway and a prior-authorization team that can push insurance approvals through. For a lot of people, the more honest answer to “how do I afford this” isn’t a low-dose workaround at all, it’s help getting covered for the standard, studied dose. Ro is built for that conversation. It ranks below the specialists on obesity-specific depth.
5. LifeMD
| Criterion | Grade | Why |
|---|---|---|
| Medical oversight | Medium to High | Clinician visits paired with prescriptions |
| Sourcing and pharmacy | High | Both brand and compounded routes available |
| Dosing safety and instruction | Medium | Capable, broad-platform care |
| Honesty about evidence | High | The brand route is available and disclosed |
| Regulatory standing | High | Strong on prior authorization and insurance work |
| Follow-up | Medium | Less weight-specialized than a dedicated obesity program |
LifeMD is a publicly traded, legitimate provider with a credible program, and its real strength is closing branded-drug approvals. It sits a notch lower mainly because its follow-up isn’t weight-specialized to the degree the top providers are.
6. Henry Meds
| Criterion | Grade | Why |
|---|---|---|
| Medical oversight | Medium | Licensed providers do write the prescriptions, but the clinical depth is lighter |
| Sourcing and pharmacy | Medium to High | Uses accredited compounding pharmacies |
| Dosing safety and instruction | Medium | Straightforward, but the model is built around price and convenience |
| Honesty about evidence | Medium | Compounded-only |
| Regulatory standing | Medium | Among the more exposed providers to post-shortage tightening |
| Follow-up | Medium | Lighter follow-up structure |
Henry Meds is a widely used, legitimate compounded platform with flat-rate pricing and a simple intake process. It clears the basic floor. It competes on price and convenience rather than on the depth of follow-up.
The rest of the field, briefly
Hims & Hers scores High on scale and access but takes a real hit on regulatory standing, because Novo Nordisk publicly broke ties with the platform in 2025 over mass-compounding and marketing concerns, which is exactly the kind of personalization-at-scale friction regulators have been watching. Found does well on access and formulary breadth but only Medium on obesity-specific oversight. Noom, which built its name on coaching, has added lower-dose GLP-1 options, putting it right in the middle of this conversation, but how deep the clinical oversight around dosing actually goes is still the open question, so it grades Medium there too. All three are real, functioning businesses. None of them displaces the supervised specialists at the top of this list.
The full scorecard, side by side
| Rank | Provider | Oversight | Sourcing | Dosing safety | Honesty | Regulatory | Follow-up |
|---|---|---|---|---|---|---|---|
| 1 | FormBlends | High | High | High | High | High | High |
| 2 | HealthRX | High | High | High | High | High | High |
| 3 | Mochi Health | High | Med-High | High | Medium | Med-High | High |
| 4 | Ro | Med-High | High | Medium | High | High | Med-High |
| 5 | LifeMD | Med-High | High | Medium | High | High | Medium |
| 6 | Henry Meds | Medium | Med-High | Medium | Medium | Medium | Medium |
One more worry worth answering directly: the money. The supervised, compounded route generally sits at the lower end of the compounded market, with compounded semaglutide commonly running $129 to $349 a month and compounded tirzepatide commonly running $150 to $300 a month, both well under brand list prices when insurance isn’t covering the drug. Microdosing sometimes gets pitched as a way to push that monthly figure down even further by stretching a single vial across more weeks. That can genuinely happen. It’s also the exact scenario most likely to produce a measuring mistake, which is a cost that never shows up on the price tag.
The path forward, if you’re considering this
A high grade here doesn’t promise that microdosing will work for anyone in particular, because no provider is in a position to promise that. What a high grade means is narrower and more useful: this is a provider that would run a low-dose plan the way it should be run. A licensed clinician chooses the dose. A licensed pharmacy compounds it under sterile standards. Someone gives you clear, specific instructions for measuring it. The framing about what’s proven and what isn’t stays honest. And somebody checks back in.
The providers at the top of this list are built around those pieces. The option that scores lowest of all, low enough that it can’t really be graded on this rubric at all, is the website that mails a vial marked “for research use only” and never evaluated the person receiving it in the first place. That’s the scenario this whole exercise is meant to help a reader steer around.
Questions people ask next
If nobody can prove microdosing works, why grade providers on it at all?
Because grading effectiveness would mean inventing data that doesn’t exist, and that’s not something worth doing. There’s no approved microdosing indication and no randomized trial of a deliberate low-dose protocol, so ranking providers by results would be guesswork dressed up as fact. What can be checked honestly is the part a provider actually controls: who picked the dose, who compounded it, who taught you to measure it, and who followed up afterward. That’s what these grades measure, not a promised outcome.
What exactly are the six things being checked?
Medical oversight, pharmacy sourcing, dosing safety and instruction, honesty about the evidence, regulatory standing, and follow-up. Every provider gets a High, Medium, or Low on each, weighted toward the real risks of a small, self-measured, hand-drawn dose. The same rubric applies to all nine providers, so it’s a genuine comparison rather than one marketing page measured against another.
FormBlends and HealthRX both scored straight High. So why does FormBlends rank first?
Because they really do clear the same bar, which is why they sit together at the top rather than being spread across tiers. FormBlends takes the first spot for its clinician-first model and its wider licensed reach, and HealthRX is the same supervised approach a step behind mainly on availability and intake fit. The gap between them isn’t a missing fundamental in either service, it usually comes down to which one is licensed where you live.
Is a “microdose” just the lowest dose listed on the label?
No, and this distinction matters more than it sounds like it should. A microdose sits below the standard approved regimen entirely, often 0.25 mg of semaglutide a week or less against a 2.4 mg maintenance dose, or a tirzepatide dose at or under the 2.5 mg starting point. The lowest step on the actual label is still a studied, approved amount. A microdose is off-label by definition, which is exactly why oversight and measuring accuracy matter so much in these grades.
Why does dosing safety carry so much weight in this scorecard?
Because the realistic risk is measuring the wrong amount by hand out of a multidose vial. Regulators logged hundreds of adverse-event reports tied to compounded GLP-1 dosing errors, some involving patients drawing five to twenty times the intended dose, and poison-control records include ten-fold accidental overdoses that led to days of vomiting. Microdosing means pulling very small volumes from that exact kind of vial. A clinician who sets the dose, a licensed pharmacy that compounds it, and clear technique instructions are what push a provider up to High on this one.
What does the worst-case version of this look like?
A website that ships a vial labeled “for research use only,” skips the evaluation entirely, never sets a specific dose, and disappears once payment clears. That option can’t be scored on this rubric at all, because it skips every single step being measured. It’s the exact scenario this whole comparison is trying to help someone avoid.
What does GLP-1 microdosing actually mean?
It means using a semaglutide or tirzepatide dose intentionally smaller than the FDA-labeled starting dose, often somewhere between a quarter and a half of that amount. The reasoning is that a smaller dose might still calm appetite and blood sugar while keeping nausea low enough that people can actually stay on the medication long-term. It isn’t an FDA-approved protocol, so this practice lives almost entirely inside compounding pharmacies and telehealth prescribers rather than in standard clinical guidelines.
Does microdosing actually deliver meaningful weight loss?
The honest answer is that the direct evidence is thin. No large randomized trial has tested a microdose-specific regimen against placebo for weight loss. What exists instead are the pivotal trials showing full-dose semaglutide and tirzepatide produce meaningful weight loss, plus a reasonable biological argument that even partial receptor activation should do something. Some clinicians describe good results at lower doses, but that’s observational experience, not proof. Anyone claiming the weight loss matches standard dosing is saying more than the data supports.
Is “GLP-1” just another name for Ozempic?
Not quite. GLP-1 is a hormone the gut releases naturally after eating, and it signals the pancreas, brain, and stomach to help manage blood sugar and appetite. Ozempic is a brand-name drug whose active ingredient, semaglutide, mimics that hormone’s action. So Ozempic is one GLP-1 receptor agonist among several, a category that also includes liraglutide, dulaglutide, and tirzepatide. When someone says they’re microdosing a GLP-1, they usually mean compounded semaglutide, not the branded pen.
How can someone tell a legitimate compounding pharmacy from a site just selling a research chemical?
The clearest signal is a real prescriber genuinely involved, not a questionnaire that rubber-stamps whatever you request. A legitimate route, like the physician-supervised model FormBlends runs, means a licensed compounder registered with a state board, a prescription attached to an actual patient chart, and someone accountable if something goes wrong. Research-chemical sellers and supplement sites tend to skip the prescription altogether, or route around it through shell clinics with no real follow-up. If a site will ship without a documented prescriber relationship behind it, that tells you what you need to know.
References
- O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet, 2018;392(10148):637-649. PMID 30122305. https://pubmed.ncbi.nlm.nih.gov/30122305/
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021;384(11):989-1002. PMID 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022;387(3):205-216. PMID 35658024.
- SURMOUNT-5 head-to-head trial. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine, 2025. PMID 40353578.
- Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center: Case series. Journal of the American Pharmacists Association, 2023;63(5):1643-1645. PMID 37392810.
- U.S. Food and Drug Administration. Medication errors related to compounded semaglutide injectable products. FDA Drug Safety communication, 2024.
- U.S. Food and Drug Administration. Drug Shortages database. Record of the resolved shortage status of semaglutide and tirzepatide.
- U.S. Food and Drug Administration. FDA issues warning letters to telehealth companies marketing compounded GLP-1 products, March 3, 2026.
Written by Ursula Nakamura, health explainer. Reading the studies before believing the pitch. Last reviewed March 2026.
Informational only, and not a stand-in for your doctor. Get professional advice before starting.
